Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics amended a Form 144 filing reporting restricted stock unit activity tied to compensation and subsequent sales by a reporting holder. The amendment lists 21,865 RSUs awarded on 01/02/2025 with a vesting/exercise-related date of 01/02/2026. The filing records dispositions by Markus Warmuth on 03/02/2026 and 04/14/2026 with reported transaction amounts of $97,974.22 and $141,124.80 respectively. The submission is an amended (144/A) notice dated 05/01/2026.
Monte Rosa Therapeutics reported insider Form 144 activity by Markus Warmuth indicating reported sales of company securities. The filing lists multiple reported transactions dated 03/02/2026, 04/14/2026, and 05/01/2026 with numeric entries 54,66, 8,000, and 5,467 respectively and associated amounts shown in the excerpt. It also lists a Stock Award (RSU) of 21,865 dated 01/02/2025 with a related date 01/02/2026.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported a small, routine option exercise and share sale. She exercised stock options to acquire 6,000 shares of common stock at $6.14 per share, then sold 6,000 shares in an open-market transaction at a weighted average price of $19.87 per share.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After the sale, Townson directly holds 67,845 shares of common stock and 209,290 stock options following the derivative transaction.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale in Common Stock. She exercised stock options for 2,175 shares at $3.98 per share and sold 2,175 shares in an open-market transaction at $20.00 per share.
After these transactions, she directly holds 62,371 shares of Common Stock and 35,649 stock options. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating a scheduled liquidity event rather than a discretionary trade.
GLUE reported a proposed sale of 2,175 shares of Common Stock via a Form 144. The filing states the shares arise from an exercise of stock options with an indicated date of 05/27/2026. The filing also lists 2,176 shares sold during the prior three months (date 05/22/2026) and an amount of $42,042.75 shown on the form.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options to acquire 2,176 shares of common stock at $3.98 per share and, on the same date, completed an open-market sale of 2,176 shares at $19.00 per share. After these transactions, she directly held 62,371 shares of Monte Rosa Therapeutics common stock. The filing notes that the transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating they were scheduled in advance.
Monte Rosa Therapeutics director Anthony M. Manning reported an option exercise-and-sale transaction in the company’s stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then sold 10,000 shares in an open-market transaction at $18.01 per share on the same date.
Following these transactions, Manning reported holding no shares of common stock directly, while retaining stock options covering 12,100 shares at a $4.16 exercise price that are fully vested and exercisable and expire on June 12, 2034.